VIVS — VivoSim Labs, Inc.

Summary of VIVS Q4 2019 Earnings Call

1. Key Financial Results and Metrics

• Net Loss: $7 million for Q4 2019, an improvement of $0.5 million compared to the same quarter in the previous year.
• Net Cash Utilization: $5.1 million, down from $5.7 million year-over-year.
• Cash and Cash Equivalents: $36.5 million as of March 31, 2019, which included $6.3 million from the issuance of 6.1 million shares in ATM offerings.
• Total Revenue: $0.7 million, a decline of 38% from the prior year, primarily due to fewer active contracts for liver tissue research services.
• R&D Expenses: Increased by 11% to $4.4 million, driven by higher lab supply costs.
• SG&A Expenses: Decreased by 25% to $3.3 million due to lower employee costs.

2. Strategic Updates and Business Highlights

• The company has revised clinical development timelines for its liver therapeutic tissue program, pushing key milestones out by several quarters.
• The first IND submission and initiation of first-in-human trials are now planned for calendar 2021, with a pre-IND meeting with the FDA expected in 2020.
• Significant progress has been made in animal studies, with over 500 rodents implanted with liver patches to evaluate functionality and viability.
• Collaborations with academic institutions continue, including a partnership with the Murdoch Children's Research Institute to develop 3D bioprinted stem cell-based therapeutic tissue for end-stage renal disease.

3. Forward Guidance and Outlook

• The company anticipates a net cash utilization rate of $20 million to $22 million for fiscal year 2020, consistent with the previous year, factoring in increased R&D spending.
• The management believes they have sufficient funds to meet operating and capital requirements through the anticipated IND submission in 2021.
• Future revenue is expected to fluctuate and likely trend down as resources are allocated primarily to liver tissue development.

4. Bad News, Challenges, or Points of Concern

• The company faces challenges with the durability and functionality of its liver tissue patches, with recent studies showing a decline in human protein output and hepatocyte counts compared to earlier pilot studies.
• The need for additional development work to enhance manufacturing processes and improve tissue viability has led to the extension of preclinical testing.
• Revenue decline and fewer active contracts indicate potential headwinds in the short term.
• The company is increasingly selective about entering new revenue-generating agreements, which may further impact revenue.

5. Notable Q&A Insights

• Management acknowledged the challenges in achieving consistent tissue viability and functionality, emphasizing the need for better measurement techniques and manufacturing process improvements.
• The decision to focus on end-stage liver disease for initial human trials was made to address a high unmet need and to potentially branch into specific diseases based on trial outcomes.
• Discussions highlighted the ongoing collaboration in renal tissue development, which is seen as an aspirational goal but will not significantly tap into company resources in the near term.

This summary encapsulates the key aspects of the earnings call, providing a balanced view of VIVS's current financial health, strategic direction, and challenges ahead.